NEU 0.07% $15.13 neuren pharmaceuticals limited

The Whens and Whys of Top Biotech M&A Deals, page-74

  1. 1,035 Posts.
    lightbulb Created with Sketch. 204
    Eagle I am sure we can run a P3 trial but the reality is we haven't done it before, so it will the first one! Secondly if we did run it successfully who is going to take it to market? who is going to negotiate with the insurance companies,? Who is going set up the clinics and triage? There is so much to consider and I do know the current management team will be learning as they go. Perhaps that might some reason the SP is going lower? Which is why I have no doubt we will get taken out, in fact if an offer does land, the board and management won't be making the decisions it will be Shareholders who make those decisions.

 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.